Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Andrew L Smith, Andre F Carvalho, Marco Solm. Methodological concerns in umbrella review of serotonin and depression. Molecular psychiatry. 2024-02-20. PMID:38374357. |
methodological concerns in umbrella review of serotonin and depression. |
2024-02-20 |
2024-02-22 |
Not clear |
Diksha Choudhary, Bhupinder Kumar, Rajwinder Kau. Nitrogen-containing heterocyclic compounds: A ray of hope in depression? Chemical biology & drug design. vol 103. issue 2. 2024-02-16. PMID:38361139. |
drugs that are currently being used for the management of various types of depression include selective serotonin reuptake inhibitors, tricyclic antidepressants, atypical antidepressants, serotonin, noradrenaline reuptake inhibitors, etc. |
2024-02-16 |
2024-02-18 |
Not clear |
Kazi Ishtiak-Ahmed, Christopher Rohde, Christian Otte, Christiane Gasse, Ole Köhler-Forsber. Comparative effectiveness of selective serotonin reuptake inhibitors (SSRIs) for depression in 43,061 older adults with chronic somatic diseases: A Danish target trial emulation study. General hospital psychiatry. vol 87. 2024-02-14. PMID:38354442. |
comparative effectiveness of selective serotonin reuptake inhibitors (ssris) for depression in 43,061 older adults with chronic somatic diseases: a danish target trial emulation study. |
2024-02-14 |
2024-02-17 |
Not clear |
Kazi Ishtiak-Ahmed, Christopher Rohde, Christian Otte, Christiane Gasse, Ole Köhler-Forsber. Comparative effectiveness of selective serotonin reuptake inhibitors (SSRIs) for depression in 43,061 older adults with chronic somatic diseases: A Danish target trial emulation study. General hospital psychiatry. vol 87. 2024-02-14. PMID:38354442. |
to investigate the comparative effectiveness of commonly used selective serotonin reuptake inhibitors (ssris) for comorbid depression in older adults with chronic somatic diseases by applying a target-trial-emulation framework. |
2024-02-14 |
2024-02-17 |
Not clear |
Tommaso Barba, Hannes Kettner, Caterina Radu, Joseph M Peill, Leor Roseman, David J Nutt, David Erritzoe, Robin Carhart-Harris, Bruna Giribald. Psychedelics and sexual functioning: a mixed-methods study. Scientific reports. vol 14. issue 1. 2024-02-07. PMID:38326446. |
it is also a common side effect of selective serotonin reuptake inhibitors (ssris), a first line treatment for depression. |
2024-02-07 |
2024-02-10 |
human |
Yi Li, Yan Yin, Yingyi Yu, Xiwen Hu, XiaoYan Liu, Sha W. The potential predictors for treatment-resistance depression after selective serotonin reuptake inhibitors therapy in Han Chinese: A resting-state functional magnetic resonance imaging study. Early intervention in psychiatry. 2024-02-06. PMID:38320861. |
the potential predictors for treatment-resistance depression after selective serotonin reuptake inhibitors therapy in han chinese: a resting-state functional magnetic resonance imaging study. |
2024-02-06 |
2024-02-09 |
Not clear |
Konstantinos N Fountoulakis, Mauricio Tohen, Carlos A Zarat. Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 81. 2024-02-04. PMID:38310714. |
the original model suggests that a constellation of effects on different receptors is necessary, but refinements, including the present study, suggest that the inhibition of the serotonin reuptake at the first level, the 5ht-2a blockade at the second level, and the norepinephrine alpha-1 receptors blockade at a third level in combination with d1 blockade contribute to the antidepressant effect in acute bipolar depression. |
2024-02-04 |
2024-02-07 |
Not clear |
Sandra Ledesma-Corvi, Jordi Jornet-Plaza, Laura Gálvez-Melero, M Julia García-Fuste. Novel rapid treatment options for adolescent depression. Pharmacological research. 2024-02-03. PMID:38309382. |
there is an urgent need for novel fast-acting antidepressants for adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved for that age (i.e., fluoxetine or escitalopram) take weeks to work. |
2024-02-03 |
2024-02-06 |
Not clear |
Sebastián García Menéndez, Walter Manuch. Vitamin D as a Modulator of Neuroinflammation: Implications for Brain Health. Current pharmaceutical design. 2024-02-02. PMID:38303529. |
lastly, its role in intestinal microbiota and serotonin synthesis contributes to psychiatric disorders like schizophrenia and depression. |
2024-02-02 |
2024-02-04 |
Not clear |
Kelly E Dunham, B Jill Vento. Electrochemical and biosensor techniques to monitor neurotransmitter changes with depression. Analytical and bioanalytical chemistry. 2024-01-30. PMID:38289354. |
three neurotransmitters: serotonin, histamine, and glutamate, have been proposed to be key mediators of depression. |
2024-01-30 |
2024-02-01 |
Not clear |
Elizabeth Lovegrove, Alice Maidwell-Smith, Beth Stuart, Miriam Sante. SSRIs in women of reproductive age; a systematic review of local formularies. BJGP open. 2024-01-25. PMID:38272494. |
depression is the second most common chronic condition affecting women of reproductive age; 23.4% of women enter pregnancy with depression and use of selective serotonin reuptake inhibitors (ssris) in pregnancy is often necessary for maternal wellbeing. |
2024-01-25 |
2024-01-28 |
Not clear |
Stefano Comai, Nicolas Nunez, Tobias Atkin, Maykel F Ghabrash, Rita Zakarian, Allan Fielding, Marie Saint-Laurent, Nancy Low, Garrett Sauber, Eugenio Ragazzi, Cecilia J Hillard, Gabriella Gobb. Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms. BMC medicine. vol 22. issue 1. 2024-01-25. PMID:38273283. |
the endocannabinoid (ecb) system and the serotonin (5-ht) are both implicated in the severity of the depression. |
2024-01-25 |
2024-01-28 |
Not clear |
Sounak Bagchi, Ehsan Nozohouri, Yeseul Ahn, Dhavalkumar Patel, Ulrich Bickel, Vardan T Karamya. Systemic and Brain Pharmacokinetics of Milnacipran in Mice: Comparison of Intraperitoneal and Intravenous Administration. Pharmaceutics. vol 16. issue 1. 2024-01-23. PMID:38258064. |
milnacipran is a dual serotonin and norepinephrine reuptake inhibitor, clinically used for the treatment of major depression or fibromyalgia. |
2024-01-23 |
2024-01-25 |
mouse |
Mariko Nakamura, Akira Yoshimi, Tatsuya Tokura, Hiroyuki Kimura, Shinichi Kishi, Tomoya Miyauchi, Kunihiro Iwamoto, Mikiko Ito, Aiji Sato-Boku, Akihiro Mouri, Toshitaka Nabeshima, Norio Ozaki, Yukihiro Nod. Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein. Pain. 2024-01-16. PMID:38227563. |
as the result, decrease of plasma serotonin concentrations may be related to the efficacy of dlx in relieving pain and depression in cop patients. |
2024-01-16 |
2024-01-19 |
Not clear |
Nune Darbinian, Nana Merabova, Gabriel Tatevosian, Mary Morrison, Armine Darbinyan, Huaqing Zhao, Laura Goetzl, Michael Edgar Selze. Biomarkers of Affective Dysregulation Associated with In Utero Exposure to EtOH. Cells. vol 13. issue 1. 2024-01-11. PMID:38201206. |
many women who use alcohol (ethanol, etoh) during pregnancy suffer from depression and take selective serotonin reuptake inhibitors (ssris), which might influence these monoaminergic pathways in the fetus. |
2024-01-11 |
2024-01-13 |
Not clear |
Volkan Uzungil, Sandra Luza, Carlos M Opazo, Isaline Mees, Shanshan Li, Ching-Seng Ang, Nicholas A Williamson, Ashley I Bush, Anthony J Hannan, Thibault Renoi. Phosphoproteomics implicates glutamatergic and dopaminergic signalling in the antidepressant-like properties of the iron chelator deferiprone. Neuropharmacology. 2024-01-06. PMID:38184274. |
polymorphisms of the serotonin transporter (5-htt) gene have been linked to depression (when combined with stressful life events) and to altered response to selective serotonergic reuptake inhibitors. |
2024-01-06 |
2024-01-09 |
mouse |
Yukiko Hori, Koki Mimura, Yuji Nagai, Yuki Hori, Katsushi Kumata, Ming-Rong Zhang, Tetsuya Suhara, Makoto Higuchi, Takafumi Minamimot. Reduced serotonergic transmission alters sensitivity to cost and reward via 5-HT1A and 5-HT1B receptors in monkeys. PLoS biology. vol 22. issue 1. 2024-01-01. PMID:38163325. |
serotonin (5-ht) deficiency is a core biological pathology underlying depression and other psychiatric disorders whose key symptoms include decreased motivation. |
2024-01-01 |
2024-01-05 |
monkey |
Evgenii Gusev, Alexey Sarapultse. Interplay of G-Proteins and Serotonin in the Neuroimmunoinflammatory Model of Chronic Stress and Depression: A Narrative Review. Current pharmaceutical design. 2023-12-28. PMID:38151838. |
interplay of g-proteins and serotonin in the neuroimmunoinflammatory model of chronic stress and depression: a narrative review. |
2023-12-28 |
2023-12-30 |
Not clear |
Ivana Jelić, Goran Mihajlović, Miloš Ratinac, Katarina Mihajlović, Sara Mijailović, Ivan Čekereva. Psychophysical and Social Functioning of Patients with Chronic Obstructive Lung Disease and Depression. European journal of investigation in health, psychology and education. vol 13. issue 12. 2023-12-22. PMID:38131895. |
this study aims to examine the relationship between the psychophysical and social functioning of copd patients who have been diagnosed with depression and the therapeutic benefits of selective serotonin reuptake inhibitors (ssris). |
2023-12-22 |
2023-12-24 |
human |
Xiaoyang Ma, Jeong-Woo Shin, Jae-Hyun Cho, Seung-Won Han, Dong-Hyun Ki. IL-6 expression-suppressing Lactobacillus reuteri strains alleviate gut microbiota-induced anxiety and depression in mice. Letters in applied microbiology. 2023-12-21. PMID:38126116. |
here, we investigated the effects of six lactobacillus reuteri strains on bdnf, serotonin, and il-6 expression in neuronal or macrophage cells and pdi fecal microbiota-cultured microbiota (pcm)-induced depression in mice. |
2023-12-21 |
2023-12-23 |
mouse |